Lonza

SIX: LONN ↗$546.40 CHF~$45B (SIX Swiss Exchange) MCAP

#Contract Manufacturing #Antibody-Drug Conjugates #Biologics #Cell & Gene Therapy #Small-Molecule API

Lonza Group AG is a Swiss multinational CDMO and contract manufacturing organization serving the pharmaceutical, biotech, and nutrition industries. In 2026 the company is expanding its antibody-drug conjugate (ADC) manufacturing capacity and broadening collaborations with US biopharma drug developers, with a focus on integrated biologics and small-molecule services.

Company Info

Sector:CDMO / Contract Manufacturing

Headquarters:Basel, Switzerland

Founded:1897

Website:www.lonza.com/

Upcoming Milestones & Key Dates

H2 2026

Earnings

H1 2026 earnings release and capacity expansion update

Clinical Development Pipeline

ADC contract manufacturing capacity expansion

Target: Integrated bioconjugate manufacturing

Service offering for client antibody-drug conjugate programs

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Lonza to expand ADC capacity, broaden collab with US drugmaker ↗

Lonza to expand ADC capacity, broaden collab with US drugmaker. (Fierce Pharma.)

Leadership Team

Wolfgang Wienand

Chief Executive Officer (since July 2024)

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →